Below is a breakdown of the primary BPC-157 protocols available at our Memorial Houston location, including how each is administered and what it is best suited for
the Akt-eNOS branch downstream of VEGFR2 has been characterised across multiple research groups, raising nitric-oxide output and supporting new vessel formation
small sample size, lack of control group, lack of common diagnosis), it did demonstrate improved pain in 87.5% of patients who received injections containing BPC-157
A 2.4 mg dose = 0.96 mL (96 units)
With internal fistulas in the colon and the bladder, with BPC 157 therapy, the colon and bladder defects showed simultaneous healing effects, including closing of the colovesical fistula in a matching healing process (Grgic et al., 2016)